Antitumor Effect of Epigallocatechin Gallate and Vincristine in Mice with L5178Y Lymphoma.

The main objective of research into new therapies is the search for more efficacy and fewer toxic effects in cancer treatments. On one hand, vincristine (VCR) is a chemotherapeutic used in different kinds of tumors. On the other hand, epigallocatechin gallate (EGCG) is a green tea metabolite that has shown an antineoplastic effect in diverse investigations, so the objective of this work is to evaluate the antitumor effects of the EGCG/VCR combination on tumor volume and survival. To achieve this objective, the solid model of lymphoma L5178Y was used in BALB/c mice with different doses of VCR, EGCG, and their combination allowed tumor growth and survival time recording. After tumor collection, measurements, and immunohistochemistry for p53, Bcl2, and Cyclin D1 were performed. The results showed that the EGCG/vincristine combination had a greater antitumor effect than those effects of vincristine and EGCG. It can be attributed to the fact that the greatest inhibition of Bcl2 was present in gathering of EGCG harvest with vincristine. Therefore, the combination of EGCG with vincristine has a better antineoplastic effect by inhibiting tumor development and increasing survival on both substances independently.

Anticancer potential of (-)-epicatechin in a triple-negative mammary gland model.

OBJECTIVES: The main aim of this work was to analyse the potential tumour growth inhibition effects of (-)-epicatechin (EC). Triple-negative breast cancer (TNBC) is an invasive form of cancer characterized by the absence of progesterone receptor, estrogen receptor and human epidermal growth factor receptor 2. Doxorubicin (DOX) is widely used for its anti-tumour activity. EC belongs to the flavanol subfamily and is a candidate molecule for the adjuvant treatment of cancer due to its antiproliferative activities. METHODS: Evaluation of EC effects and pathways involved in a model of TNBC. KEY FINDINGS: EC inhibited tumour growth as efficiently as DOX (inhibition rates of 74% and 79% for EC and DOX, respectively). The evaluation of adenosine monophosphate-activated protein kinase (AMPK) and Akt phosphorylation and mTOR expression indicates that EC modulates these pathways, resulting in the inhibition of cell proliferation. Additionally, we found an increase in the survival of EC-treated animals compared with control-treated animals. This effect was similar to the effects induced by DOX (survival rates of 44% and 30% for EC and DOX, respectively). CONCLUSION: EC has antiproliferative properties and increases survival in a model of TNBC. These effects may occur through the modulation of deregulated AMPK and Akt/mTOR signalling pathways.

Geraniin is a diuretic by inhibiting the Na+-K+-2Cl- cotransporter NKCC2.

Geranium seemannii Peyr is a perennial plant endemic to central Mexico that has been widely used for its diuretic effect, but the responsible compound of this effect is unknown as well as the mechanism by which the diuretic effect is achieved. Geraniin is one of the compounds isolated from this kind of geranium. This study was designed to determinate whether geraniin possesses diuretic activity and to elucidate the mechanism of action. Geraniin was extracted and purified from Geranium seemannii Peyr. Male Wistar rats were divided into four groups: 1) Control, 2) 75 mg/kg of geraniin, 3) 20 mg/kg of furosemide, and 4) 10 mg/kg of hydrochlorothiazide. Each treatment was administered by gavage every 24 h for 7 days. The urinary excretion of electrolytes and the fractional excretion of sodium (FENa) were determined. To uncover the molecular target of geraniin, Xenopus laevis oocytes were microinjected with cRNAs encoding the Na+-Cl- cotransporter (NCC) and the Na+-K+-2Cl- cotransporter NKCC2 to functionally express these cotransporters. Geraniin significantly increased diuresis, natriuresis, and calciuresis to a similar extent as was observed in the furosemide-treated rats. Consistent with the furosemide-like effect, in X. laevis oocytes, geraniin significantly reduced the activity of NKCC2, with no effect on NCC activity. In contrast to furosemide, the effect of geraniin on NKCC2 was irreversible, apparently due to its inhibitory effect on heat shock protein 90. Our observations suggest that geraniin could have a potential role in the treatment of hypertension or edematous states.

Análisis fitoquímico de Jatropha dioica y determinación de su efectoantioxidante y quimioprotector sobre el potencial genotóxico deciclofosfamida, daunorrubicina y metilmetanosulfonato evaluadomediante el ensayo cometa / Phytochemical analysis of Jatropha dioica and determination of its antioxidant and chemopreventive effect on the genotoxic potential of cyclophosphamide, daunorubicin and methyl methane-sulfonate evaluated by the comet assay

Dragon ́s blood root (Jatropha dioica) underwent a phytochemical screening showing the presence of flavonoids and terpenes responsible for the antioxidant potential observed in DPPH model for the decoction, aqueous and methanolic extracts. The chemoprotective effect of the root decoction was evaluated in liver, kidney and bone marrow cells of mice using the comet assay. Mutagens were administered via IP: cyclophosphamide (CCF) 50 mg/kg, daunorubicin (DAU) 10 mg/kg, and metyl metanesulfonate (MMS) 40 mg/kg, were co-administered with three doses of decoction 3.72 ml/kg, 10.71 ml/kg, and 21.42 ml/kg orally. Animals were sacrificed at 3, 9, 15 and 21 h after inoculation. The chemoprotective effect decreased DNA breaks at 3 hours in all organs, and longer against CCF and DAU, this effect probably being related to the antioxidant capacity of the decoction.

La raíz de Sangre de Drago (Jatropha dioica) se sometió a un tamizaje fitoquímico destacando la presencia de flavonoides y terpenos, posibles responsables del efecto antioxidante observado en el modelo de DPPH para la decocción, extracto acuoso y metanólico de la raíz. El efecto quimioprotector de la decocción, se evaluó en células hepáticas, renales y de médula ósea de ratón, mediante el ensayo cometa. Los mutágenos administrados vía I.P.: ciclofosfamida (CCF) 50 mg/kg, daunorrubicina (DAU) 10 mg/kg y metilmetanosulfonato (MMS) 40 mg/kg, se co-administraron con tres dosis de decocción 3,72 ml/kg, 10,71 ml/kg y 21,42 ml/kg, vía oral. Los animales fueron sacrificados a las 3, 9, 15 y 21 h posteriores a la aplicación. El efecto quimioprotector disminuyó las rupturas del DNA a las 3 horas en todos los órganos con los tres mutágenos, y permaneció por más tiempo frente a CCF y DAU, dicho efecto está relacionado con la capacidad antioxidante de la decocción.